Drugs Made In America Acquisition II Corp. Reports $4.34 Million Net Income in Q1 2026

Drugs Made In America Acquisition II Corp. reported a net income of $4.34 million for the first quarter of 2026, a significant turnaround from a net loss of $59,327 in the same period last year. The company attributed this positive performance primarily to $4.44 million in interest earned on cash and investments held in its trust account, which was established following its initial public offering (IPO) in September 2025. Operating expenses for the quarter totaled $132,030, up from $59,327 in the prior year, reflecting increased administrative costs as the company prepares for its planned business combination.

The company’s total assets as of March 31, 2026, stood at approximately $509.73 million, a slight increase from $504.96 million at the end of 2025. This growth was driven by cash and investments held in the trust account, which rose to $509.37 million from $504.93 million. Current liabilities also increased, reaching $666,285 compared to $300,864 at the end of the previous year, largely due to the issuance of promissory notes totaling $450,000.

Drugs Made In America Acquisition II Corp. has not yet identified a target for its initial business combination, which is a key focus of its strategy. The company is positioned as a blank check company, primarily targeting opportunities within the pharmaceutical industry. As of March 31, 2026, the company had 13.7 million ordinary shares outstanding, with an additional 50 million shares subject to possible redemption at a value of $10.19 per share. The company’s management has indicated that it will utilize the funds from its trust account to finance the acquisition of a target business.

Looking ahead, the company faces significant challenges, including the need to complete a business combination within 24 months of its IPO. If it fails to do so, it will be required to liquidate and redeem public shares. The management has expressed concerns regarding its ability to continue as a going concern, citing substantial costs associated with remaining a publicly traded entity and the uncertainties surrounding the completion of a business combination. The company has also noted that it may need to raise additional funds to cover operational costs or to facilitate a business combination, which could involve issuing new securities or incurring debt.